Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, nasal, patch, foam, buccal, sublingual, suspensions, soft gel, injectable, and oral dosages. It also provides its products for various medical indications, such as analgesic, anti-psychosis, cardiovascular, central nervous system, endocrinology, gastrointestinal, infectious disease, migraine, respiratory/allergy/cough/cold, urinary, and others medical indications. The company's primary products include Levothyroxine Sodium tablets, Fluphenazine tablets, Posaconazole DR tablets, Verapamil SR tablets, Methylphenidate CD capsules, Omeprazole capsules, Pantoprazole Sodium DR tablets, Sumatriptan Nasal spray, Metolazone tablets, Amphetamine IR Tablets, Methylphenidate Hydrochloride ER stimulants, as well as cocaine hydrochloride solution. It sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical companies, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. The company has supply and development agreements with Summit Bioscience LLC, HEC Group of companies, Dexcel Pharma, Elite Pharmaceuticals, RivoPharm, and various other companies. Lannett Company, Inc. was incorporated in 1942 and is headquartered in Trevose, Pennsylvania.
Revenue of Lannett Company, Inc. (LCI)
Revenue in 2022 (TTM): $340.58 M
According to Lannett Company, Inc.'s latest financial reports the company's current revenue (TTM) is $340.58 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Lannett Company, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2022 | $340.58 M | $33.17 M | $-176,273,000 | $-233,924,000 | $-231,620,000 |
| 2021 | $478.78 M | $75.59 M | $-18,322,000 | $-302,850,000 | $-363,475,000 |
| 2020 | $545.74 M | $165.22 M | $54.94 M | $-48,628,000 | $-33,366,000 |
| 2019 | $655.41 M | $243.61 M | $115.14 M | $-346,245,000 | $-272,107,000 |
| 2018 | $684.56 M | $288.71 M | $191.84 M | $51.09 M | $28.69 M |
| 2017 | $637.34 M | $305.21 M | $145.28 M | $550 K | $-581,000 |
| 2016 | $566.09 M | $310.09 M | $161.47 M | $62.18 M | $44.78 M |
| 2015 | $406.84 M | $306.36 M | $233.14 M | $227.42 M | $149.92 M |
| 2014 | $273.77 M | $154.41 M | $96.07 M | $90.02 M | $57.1 M |
| 2013 | $151.05 M | $57.42 M | $27.07 M | $20.69 M | $13.32 M |
| 2012 | $122.99 M | $38.95 M | $12.56 M | $6.62 M | $3.95 M |
| 2011 | $106.84 M | $23.32 M | $4.45 M | $-701,368 | $-276,900 |
| 2010 | $125.18 M | $41.34 M | $17.8 M | $12.82 M | $7.82 M |
| 2009 | $119 M | $45.24 M | $16.05 M | $10.67 M | $6.53 M |
| 2008 | $72.4 M | $18.32 M | $-464,712 | $-5,643,761 | $-2,318,059 |
| 2007 | $82.58 M | $25.18 M | $-1,455,686 | $-5,921,079 | $-6,929,008 |
| 2006 | $64.06 M | $30.16 M | $12.5 M | $8.53 M | $4.97 M |
| 2005 | $44.9 M | $13.48 M | $-46,854,566 | $-53,825,498 | $-32,779,596 |
| 2004 | $63.78 M | $36.92 M | $23.32 M | $20.81 M | $13.22 M |
| 2003 | $42.49 M | $26.23 M | $19.98 M | $19 M | $11.67 M |
| 2002 | $25.13 M | $16.67 M | $11.97 M | $11.18 M | $7.2 M |
| 2001 | $12.09 M | $5.56 M | $3.6 M | $2.84 M | $1.83 M |
| 2000 | $11.55 M | $3.66 M | $1.56 M | $884.77 K | $1.35 M |
| 1999 | $10.6 M | $4 M | $1.5 M | $900 K | $1.3 M |
| 1998 | $9.46 M | $3.34 M | $1.25 M | $875.72 K | $1.03 M |
| 1997 | $3.8 M | $1.16 M | $-582,654 | $-150,882 | $-789,340 |
| 1996 | $3.82 M | $1.95 M | $341.33 K | $137.07 K | $137.07 K |